Europe Stroke Market - Industry Trends and Forecast to 2032

Description

List of Tables

Europe stroke market is projected to register a CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland and Rest of Europe) - Industry trends and forecast to 2030.

Overview of Europe Stroke Market Dynamics

Drivers
Rising incidences of stroke
Increasing number of patients with hypertension and coronary heart diseases
Restraints
High cost associated with treatment of stroke
Side-effects associated with medication
Opportunities
Expansion of telemedicine and remote monitoring
Innovative therapies in pipeline for stroke treatment

Market Players

Some of the major market players operating in the Europe stroke market are:

Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH.
F. Hoffmann-La Roche Ltd
DAIICHI SANKYO COMPANY, LIMITED.
Sanofi
Johnson & Johnson Services, Inc.
Bayer AG
Sandoz AG
Pfizer Inc.
Medtronic
Abbott
Viatris Inc.
AstraZeneca
Penumbra, Inc.
GLENMARK PHARMACEUTICALS LTD
Fresenius Kabi USA

1 INTRODUCTION 39

1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF THE EUROPE STROKE MARKET 39
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 41

2 MARKET SEGMENTATION 46

2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 TYPE LIFELINE CURVE 53
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 55
2.10 MARKET APPLICATION COVERAGE GRID 56
2.11 VENDOR SHARE ANALYSIS 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58

3 EXECUTIVE SUMMARY 59

4 PREMIUM INSIGHTS 62

4.1 PESTEL'S MODEL 63
4.2 PORTER'S 5 FORCES 64

5 EPIDEMIOLOGY 65

6 EUROPE STROKE MARKET, REGULATORY FRAMEWORK 66

6.1 REGULATION IN U.S 66
6.2 REGULATION IN EUROPE 67
6.3 REGULATION IN CHINA 68
6.4 REGULATION IN JAPAN 69
6.5 REGULATION IN SOUTH AFRICA 70

7 MARKET OVERVIEW 71

7.1 DRIVERS 73
- 7.1.1 RISING INCIDENCES OF STROKE 73
- 7.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 74
- 7.1.3 INCREASING DIABETIC AND OBESE POPULATION 75
- 7.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR STROKE TREATMENT 76
7.2 RESTRAINTS 77
- 7.2.1 HIGH COST ASSOCIATED WITH TREATMENT OF STROKE 77
- 7.2.2 SIDE-EFFECTS ASSOCIATED WITH MEDICATION 78
7.3 OPPORTUNITIES 79
- 7.3.1 EXPANSION OF TELEMEDICINE AND REMOTE MONITORING 79
- 7.3.2 INNOVATIVE THERAPIES IN PIPELINE FOR STROKE TREATMENT 79
7.4 CHALLENGES 80
- 7.4.1 INACCURATE DIAGNOSIS OF STROKES S 80
- 7.4.2 COMPLICATIONS IN MANAGING STROKE IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS 81

8 EUROPE STROKE MARKET, BY TYPE 82

8.1 OVERVIEW 83
8.2 ISCHEMIC STROKE 86
- 8.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 87
- 8.2.2 EMBOLIC (CEREBRAL EMBOLISM) 87
8.3 HEMORRHAGIC STROKE 88
- 8.3.1 SUBARACHNOID HEMORRHAGE 89
- 8.3.2 INTRACEREBRAL HEMORRHAGE 89
8.4 TRANSIENT ISCHEMIC ATTACK (TIA) 89

9 EUROPE STROKE MARKET, BY TREATMENT 90

9.1 OVERVIEW 91
9.2 MEDICATION 94
- 9.2.1 BY CLASS 95
  - 9.2.1.1 BLOOD PRESSURE MEDICINES 96
    - 9.2.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 97
    - 9.2.1.1.1.1 RAMIPRIL 97
    - 9.2.1.1.1.2 LISINOPRIL 97
    - 9.2.1.1.1.3 ENALAPRIL 97
    - 9.2.1.1.1.4 PERINDOPRIL 97
    - 9.2.1.1.1.5 OTHER 98
    - 9.2.1.1.2 DIURETICS 98
    - 9.2.1.1.2.1 INDAPAMIDE 98
    - 9.2.1.1.2.2 BENDROFLUMETHIAZIDE 98
    - 9.2.1.1.2.3 SPIRONOLACTONE 98
    - 9.2.1.1.2.4 AMILORIDE 99
    - 9.2.1.1.2.5 OTHER 99
    - 9.2.1.1.3 CALCIUM CHANNEL BLOCKERS 99
    - 9.2.1.1.3.1 AMLODIPINE 99
    - 9.2.1.1.3.2 NIFEDIPINE 99
    - 9.2.1.1.3.3 VERAPAMIL 100
    - 9.2.1.1.3.4 NICARDIPINE 100
    - 9.2.1.1.3.5 FELODIPINE 100
    - 9.2.1.1.3.6 NIMODIPINE 100
    - 9.2.1.1.3.7 OTHER 100
    - 9.2.1.1.4 BETA BLOCKERS 101
    - 9.2.1.1.4.1 ATENOLOL 101
    - 9.2.1.1.4.2 BISOPROLOL 101
    - 9.2.1.1.4.3 LABETOLOL 101
    - 9.2.1.1.4.4 OTHER 101
    - 9.2.1.1.5 ALPHA BLOCKERS 102
    - 9.2.1.1.5.1 DOXAZOSIN 102
    - 9.2.1.1.5.2 OTHER 102
    - 9.2.1.1.6 OTHERS 102
  - 9.2.1.1 ANTIPLATELET DRUGS 103
    - 9.2.1.1.1 ASPIRIN 103
    - 9.2.1.1.2 CLOPIDOGREL 103
    - 9.2.1.1.3 DIPYRIDAMOLE 103
    - 9.2.1.1.4 TICLOPIDINE 103
    - 9.2.1.1.5 OTHERS 103
  - 9.2.1.2 ANTICOAGULANTS 104
    - 9.2.1.2.1 WARFARIN 104
    - 9.2.1.2.2 APIXABAN 104
    - 9.2.1.2.3 DABIGATRAN 104
    - 9.2.1.2.4 HEPARIN 104
    - 9.2.1.2.5 RIVAROXABAN 105
    - 9.2.1.2.6 OTHERS 105
  - 9.2.1.3 TISSUE PLASMINOGEN ACTIVATOR (TPA) 105
    - 9.2.1.3.1 ALTEPLASE 105
    - 9.2.1.3.2 TENECTEPLASE 105
    - 9.2.1.3.3 RETEPLASE 105
    - 9.2.1.3.4 ANISTREPLASE 106
    - 9.2.1.3.5 OTHERS 106
  - 9.2.1.4 STATINS 106
    - 9.2.1.4.1 ATORVASTATIN 106
    - 9.2.1.4.2 SIMVASTATIN 106
    - 9.2.1.4.3 LOVASTATIN 106
    - 9.2.1.4.4 ROSUVASTATIN 107
    - 9.2.1.4.5 FLUVASTATIN 107
    - 9.2.1.4.6 PRAVASTATIN 107
    - 9.2.1.4.7 PITAVASTATIN 107
    - 9.2.1.4.8 OTHERS 107
  - 9.2.1.5 VITAMIN K 107
  - 9.2.1.6 SUPPORTIVE MEDICATION 108
    - 9.2.1.6.1 NUTRITIONAL SUPPLEMENTS 108
    - 9.2.1.6.2 ANTIPYRETICS 108
    - 9.2.1.6.3 OTHERS 108
- 9.2.2 BY DRUG TYPE 109
  - 9.2.2.1 GENERICS 109
  - 9.2.2.2 BRANDED 110
    - 9.2.2.2.1 ELIQUIS 110
    - 9.2.2.2.2 PRADAXA 110
    - 9.2.2.2.3 ACTIVASE 110
    - 9.2.2.2.4 ASPIRIN 111
    - 9.2.2.2.5 PLAVIX 111
    - 9.2.2.2.6 AGGRENOX 111
    - 9.2.2.2.7 OTHERS 111
- 9.2.3 BY ROUTE OF ADMINISTRATION 112
  - 9.2.3.1 ORAL 112
    - 9.2.3.1.1 TABLET 113
    - 9.2.3.1.2 CAPSULES 113
    - 9.2.3.1.3 Others 113
  - 9.2.3.2 PARENTERAL 114
    - 9.2.3.2.1 INTRAVENOUS 114
    - 9.2.3.2.2 SUBCUTANEOUS 114
  - 9.2.3.3 OTHERS 114
- 9.2.4 BY MODE OF PURCHASE 115
  - 9.2.4.1 PRESCRIPTION 115
  - 9.2.4.2 OVER THE COUNTER (OTC) 115
- 9.2.5 BY THERPAY TYPE 116
  - 9.2.5.1 COMBINATION THERAPY 116
  - 9.2.5.2 MONOTHERAPY 116
9.3 SURGERY 117
- 9.3.1 EMBOLIC COILS 118
- 9.3.2 ASPIRATION CATHETERS 118
- 9.3.3 STENT RETRIEVER 118
- 9.3.4 SURGICAL CLIPPING 118
- 9.3.5 OTHERS 118
9.4 OTHER THERAPY 119
- 9.4.1 PHYSICAL THERAPY 119
- 9.4.2 OCCUPATIONAL THERAPY 119
- 9.4.3 SPEECH THERAPY 120
- 9.4.4 OTHERS 120

10 EUROPE STROKE MARKET, BY DIAGNOSIS 121

10.1 OVERVIEW 122
10.2 IMAGING TEST 125
- 10.2.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 125
- 10.2.2 MAGNETIC RESONANCE IMAGING (MRI) 126
- 10.2.3 CAROTID ULTRASOUND 126
- 10.2.4 CEREBRAL ANGIOGRAM 126
10.3 BLOOD TEST 127
10.4 ECHOCARDIOGRAM 127
10.5 LUMBAR PUNCTURE 128
10.6 OTHERS 128

11 EUROPE STROKE MARKET, BY GENDER 129

11.1 OVERVIEW 130
11.2 FEMALE 133
11.3 MALE 134

12 EUROPE STROKE MARKET, BY END USER 135

12.1 OVERVIEW 136
12.2 HOSPITALS & CLINICS 139
12.3 SPECIALTY CLINICS 140
12.4 AMBULATORY SURGICAL CENTER 140
12.5 HOMECARE 141
12.6 LABORATORIES 141
12.7 OTHERS 142

13 EUROPE STROKE MARKET, BY DISTRIBUTION CHANNEL 143

13.1 OVERVIEW 144
13.2 DIRECT 147
13.3 RETAIL 147
13.4 ONLINE 148

14 EUROPE STROKE MARKET, BY REGION 149

14.1 EUROPE 151
- 14.1.1 GERMANY 164
- 14.1.2 U.K. 175
- 14.1.3 FRANCE 186
- 14.1.4 RUSSIA 198
- 14.1.5 ITALY 210
- 14.1.6 SPAIN 222
- 14.1.7 TURKEY 234
- 14.1.8 POLAND 245
- 14.1.9 BELGIUM 256
- 14.1.10 NETHERLANDS 267
- 14.1.11 SWITZERLAND 278
- 14.1.12 DENMARK 290
- 14.1.13 SWEDEN 301
- 14.1.14 NORWAY 312
- 14.1.15 FINLAND 324
- 14.1.16 REST OF EUROPE 336

15 EUROPE STROKE MARKET, COMPANY LANDSCAPE 337

15.1 COMPANY SHARE ANALYSIS: EUROPE 337

16 SWOT ANALYSIS 338

17 COMPANY PROFILES 339

17.1 BRISTOL-MYERS SQUIBB COMPANY 339
- 17.1.1 COMPANY SNAPSHOT 339
- 17.1.2 REVENUE ANALYSIS 339
- 17.1.3 COMPANY SHARE ANALYSIS 340
- 17.1.4 PRODUCT PORTFOLIO 340
- 17.1.5 RECENT DEVELOPMENT 341
17.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 342
- 17.2.1 COMPANY SNAPSHOT 342
- 17.2.2 PRODUCT PORTFOLIO 342
- 17.2.3 COMPANY SHARE ANALYSIS 343
- 17.2.4 RECENT DEVELOPMENT 343
17.3 F. HOFFMANN-LA ROCHE LTD 344
- 17.3.1 COMPANY SNAPSHOT 344
- 17.3.2 REVENUE ANALYSIS 344
- 17.3.3 COMPANY SHARE ANALYSIS 345
- 17.3.4 PRODUCT PORTFOLIO 345
- 17.3.5 RECENT DEVELOPMENT 345
17.4 DAIICHI SANKYO COMPANY, LIMITED 346
- 17.4.1 COMPANY SNAPSHOT 346
- 17.4.2 REVENUE ANALYSIS 346
- 17.4.3 COMPANY SHARE ANALYSIS 347
- 17.4.4 PRODUCT PORTFOLIO 347
- 17.4.5 RECENT DEVELOPMENT 348
17.5 SANOFI 349
- 17.5.1 COMPANY SNAPSHOT 349
- 17.5.2 REVENUE ANALYSIS 349
- 17.5.3 COMPANY SHARE ANALYSIS 350
- 17.5.4 PRODUCT PORTFOLIO 350
- 17.5.5 RECENT DEVELOPMENT 350
17.6 ABBOTT 352
- 17.6.1 COMPANY SNAPSHOT 352
- 17.6.2 REVENUE ANALYSIS 352
- 17.6.3 PRODUCT PORTFOLIO 353
- 17.6.4 RECENT DEVELOPMENT 354
17.7 AMNEAL PHARMACEUTICALS LLC 355
- 17.7.1 COMPANY SNAPSHOT 355
- 17.7.2 REVENUE ANALYSIS 355
- 17.7.3 PRODUCT PORTFOLIO 356
- 17.7.4 RECENT DEVELOPMENT 356
17.8 ASTRAZENECA 357
- 17.8.1 COMPANY SNAPSHOT 357
- 17.8.2 REVENUE ANALYSIS 358
- 17.8.3 PRODUCT PORTFOLIO 358
- 17.8.4 RECENT DEVELOPMENT 358

17.9 BAYER AG 359
- 17.9.1 COMPANY SNAPSHOT 359
- 17.9.2 REVENUE ANALYSIS 360
- 17.9.3 PRODUCT PORTFOLIO 360
- 17.9.4 RECENT DEVELOPMENT 361
17.10 FRESENIUS SE & CO. KGAA 362
- 17.10.1 COMPANY SNAPSHOT 362
- 17.10.2 REVENUE ANALYSIS 362
- 17.10.3 PRODUCT PORTFOLIO 363
- 17.10.4 RECENT DEVELOPMENT 363
17.11 GLENMARK PHARMACEUTICALS LTD. 364
- 17.11.1 COMPANY SNAPSHOT 364
- 17.11.2 REVENUE ANALYSIS 365
- 17.11.3 PRODUCT PORTFOLIO 365
- 17.11.4 RECENT DEVELOPMENT 365
17.12 JOHNSON & JOHNSON SERVICES, INC. 367
- 17.12.1 COMPANY SNAPSHOT 367
- 17.12.2 REVENUE ANALYSIS 367
- 17.12.3 PRODUCT PORTFOLIO 368
- 17.12.4 RECENT DEVELOPMENT 368
17.13 LUPIN 369
- 17.13.1 COMPANY SNAPSHOT 369
- 17.13.2 REVENUE ANALYSIS 369
- 17.13.3 PRODUCT PORTFOLIO 370
- 17.13.4 RECENT DEVELOPMENT 371
17.14 MEDTRONIC 372
- 17.14.1 COMPANY SNAPSHOT 372
- 17.14.2 REVENUE ANALYSIS 372
- 17.14.3 PRODUCT PORTFOLIO 373
- 17.14.4 RECENT DEVELOPMENT 373
17.15 OXFORD LABORATORIES PVT. LTD. 374
- 17.15.1 COMPANY SNAPSHOT 374
- 17.15.2 PRODUCT PORTFOLIO 374
- 17.15.3 RECENT DEVELOPMENT 374
17.16 PENUMBRA, INC. 375
- 17.16.1 COMPANY SNAPSHOT 375
- 17.16.2 REVENUE ANALYSIS 375
- 17.16.3 PRODUCT PORTFOLIO 376
- 17.16.4 RECENT DEVELOPMENT 376

17.17 PFIZER INC. 377
- 17.17.1 COMPANY SNAPSHOT 377
- 17.17.2 REVENUE ANALYSIS 377
- 17.17.3 PRODUCT PORTFOLIO 378
- 17.17.4 RECENT DEVELOPMENT 378
17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 379
- 17.18.1 COMPANY SNAPSHOT 379
- 17.18.2 REVENUE ANALYSIS 379
- 17.18.3 PRODUCT PORTFOLIO 380
- 17.18.4 RECENT DEVELOPMENT 380
17.19 TEVA PHARMACEUTICALS USA, INC. 381
- 17.19.1 COMPANY SNAPSHOT 381
- 17.19.2 REVENUE ANALYSIS 381
- 17.19.3 PRODUCT PORTFOLIO 382
- 17.19.4 RECENT DEVELOPMENT 382
17.20 VIATRIS INC. 383
- 17.20.1 COMPANY SNAPSHOT 383
- 17.20.2 REVENUE ANALYSIS 383
- 17.20.3 PRODUCT PORTFOLIO 384
- 17.20.4 RECENT DEVELOPMENT 384

18 QUESTIONNAIRE 385

19 RELATED REPORTS 389

17.9 BAYER AG 359
- 17.9.1 COMPANY SNAPSHOT 359
- 17.9.2 REVENUE ANALYSIS 360
- 17.9.3 PRODUCT PORTFOLIO 360
- 17.9.4 RECENT DEVELOPMENT 361
17.10 FRESENIUS SE & CO. KGAA 362
- 17.10.1 COMPANY SNAPSHOT 362
- 17.10.2 REVENUE ANALYSIS 362
- 17.10.3 PRODUCT PORTFOLIO 363
- 17.10.4 RECENT DEVELOPMENT 363
17.11 GLENMARK PHARMACEUTICALS LTD. 364
- 17.11.1 COMPANY SNAPSHOT 364
- 17.11.2 REVENUE ANALYSIS 365
- 17.11.3 PRODUCT PORTFOLIO 365
- 17.11.4 RECENT DEVELOPMENT 365
17.12 JOHNSON & JOHNSON SERVICES, INC. 367
- 17.12.1 COMPANY SNAPSHOT 367
- 17.12.2 REVENUE ANALYSIS 367
- 17.12.3 PRODUCT PORTFOLIO 368
- 17.12.4 RECENT DEVELOPMENT 368
17.13 LUPIN 369
- 17.13.1 COMPANY SNAPSHOT 369
- 17.13.2 REVENUE ANALYSIS 369
- 17.13.3 PRODUCT PORTFOLIO 370
- 17.13.4 RECENT DEVELOPMENT 371
17.14 MEDTRONIC 372
- 17.14.1 COMPANY SNAPSHOT 372
- 17.14.2 REVENUE ANALYSIS 372
- 17.14.3 PRODUCT PORTFOLIO 373
- 17.14.4 RECENT DEVELOPMENT 373
17.15 OXFORD LABORATORIES PVT. LTD. 374
- 17.15.1 COMPANY SNAPSHOT 374
- 17.15.2 PRODUCT PORTFOLIO 374
- 17.15.3 RECENT DEVELOPMENT 374
17.16 PENUMBRA, INC. 375
- 17.16.1 COMPANY SNAPSHOT 375
- 17.16.2 REVENUE ANALYSIS 375
- 17.16.3 PRODUCT PORTFOLIO 376
- 17.16.4 RECENT DEVELOPMENT 376

17.17 PFIZER INC. 377
- 17.17.1 COMPANY SNAPSHOT 377
- 17.17.2 REVENUE ANALYSIS 377
- 17.17.3 PRODUCT PORTFOLIO 378
- 17.17.4 RECENT DEVELOPMENT 378
17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 379
- 17.18.1 COMPANY SNAPSHOT 379
- 17.18.2 REVENUE ANALYSIS 379
- 17.18.3 PRODUCT PORTFOLIO 380
- 17.18.4 RECENT DEVELOPMENT 380
17.19 TEVA PHARMACEUTICALS USA, INC. 381
- 17.19.1 COMPANY SNAPSHOT 381
- 17.19.2 REVENUE ANALYSIS 381
- 17.19.3 PRODUCT PORTFOLIO 382
- 17.19.4 RECENT DEVELOPMENT 382
17.20 VIATRIS INC. 383
- 17.20.1 COMPANY SNAPSHOT 383
- 17.20.2 REVENUE ANALYSIS 383
- 17.20.3 PRODUCT PORTFOLIO 384
- 17.20.4 RECENT DEVELOPMENT 384

18 QUESTIONNAIRE 385

19 RELATED REPORTS 389

LIST OF FIGURES

FIGURE 1 EUROPE STROKE MARKET: SEGMENTATION 46
FIGURE 2 EUROPE STROKE MARKET: DATA TRIANGULATION 49
FIGURE 3 EUROPE STROKE MARKET: DROC ANALYSIS 50
FIGURE 4 EUROPE STROKE MARKET : EUROPE VS REGIONAL MARKET ANALYSIS 51
FIGURE 5 EUROPE STROKE MARKET: COMPANY RESEARCH ANALYSIS 51
FIGURE 6 EUROPE STROKE MARKET: INTERVIEW DEMOGRAPHICS 54
FIGURE 7 EUROPE STROKE MARKET: DBMR MARKET POSITION GRID 55
FIGURE 8 EUROPE STROKE MARKET: MARKET APPLICATION COVERAGE GRID 56
FIGURE 9 EUROPE STROKE MARKET: VENDOR SHARE ANALYSIS 57
FIGURE 10 EUROPE STROKE MARKET: SEGMENTATION 61
FIGURE 11 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE IS EXPECTED TO DRIVE THE EUROPE STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 62
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE STROKE MARKET IN THE FORECAST PERIOD OF 2023 & 2030 62
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE STROKE MARKET 72
FIGURE 14 EUROPE STROKE MARKET: BY TYPE, 2022 83
FIGURE 15 EUROPE STROKE MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 84
FIGURE 16 EUROPE STROKE MARKET: BY TYPE, CAGR (2023-2030) 84
FIGURE 17 EUROPE STROKE MARKET: BY TYPE, LIFELINE CURVE 85
FIGURE 18 EUROPE STROKE MARKET: BY TREATMENT, 2022 91
FIGURE 19 EUROPE STROKE MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 92
FIGURE 20 EUROPE STROKE MARKET: BY TREATMENT, CAGR (2023-2030) 92
FIGURE 21 EUROPE STROKE MARKET: BY TREATMENT, LIFELINE CURVE 93
FIGURE 22 EUROPE STROKE MARKET: BY DIAGNOSIS, 2022 122
FIGURE 23 EUROPE STROKE MARKET: BY DIAGNOSIS, 2023-2030 (USD THOUSAND) 123
FIGURE 24 EUROPE STROKE MARKET: BY DIAGNOSIS, CAGR (2023-2030) 123
FIGURE 25 EUROPE STROKE MARKET: BY DIAGNOSIS, LIFELINE CURVE 124
FIGURE 26 EUROPE STROKE MARKET: BY GENDER, 2022 130
FIGURE 27 EUROPE STROKE MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 131
FIGURE 28 EUROPE STROKE MARKET: BY GENDER, CAGR (2023-2030) 131
FIGURE 29 EUROPE STROKE MARKET: BY GENDER, LIFELINE CURVE 132
FIGURE 30 EUROPE STROKE MARKET: BY END USER, 2022 136
FIGURE 31 EUROPE STROKE MARKET: BY END USER, 2023-2030 (USD THOUSAND) 137
FIGURE 32 EUROPE STROKE MARKET: BY END USER, CAGR (2023-2030) 137
FIGURE 33 EUROPE STROKE MARKET: BY END USER, LIFELINE CURVE 138
FIGURE 34 EUROPE STROKE MARKET: BY DISTRIBUTION CHANNEL, 2022 144
FIGURE 35 EUROPE STROKE MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 145
FIGURE 36 EUROPE STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 145
FIGURE 37 EUROPE STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 146
FIGURE 38 EUROPE STROKE MARKET: SNAPSHOT (2022) 150
FIGURE 39 EUROPE STROKE MARKET: COMPANY SHARE 2022 (%) 337

Europe Stroke Market - Industry Trends and Forecast to 2032

Description

Table of Contents

List of Tables

Market Segmentation:

Overview of Europe Stroke Market Dynamics

Market Players

Some of the major market players operating in the Europe stroke market are:

TABLE OF CONTENTS

1 INTRODUCTION 39

2 MARKET SEGMENTATION 46

3 EXECUTIVE SUMMARY 59

4 PREMIUM INSIGHTS 62

5 EPIDEMIOLOGY 65

6 EUROPE STROKE MARKET, REGULATORY FRAMEWORK 66

7 MARKET OVERVIEW 71

8 EUROPE STROKE MARKET, BY TYPE 82

9 EUROPE STROKE MARKET, BY TREATMENT 90

10 EUROPE STROKE MARKET, BY DIAGNOSIS 121

11 EUROPE STROKE MARKET, BY GENDER 129

12 EUROPE STROKE MARKET, BY END USER 135

13 EUROPE STROKE MARKET, BY DISTRIBUTION CHANNEL 143

14 EUROPE STROKE MARKET, BY REGION 149

15 EUROPE STROKE MARKET, COMPANY LANDSCAPE 337

16 SWOT ANALYSIS 338

17 COMPANY PROFILES 339

18 QUESTIONNAIRE 385

19 RELATED REPORTS 389

18 QUESTIONNAIRE 385

19 RELATED REPORTS 389

LIST OF FIGURES